By Yutaka Iimura,Senior Fellow at GRIPS Alliance,Visiting Professor at National Graduate Institute for Policy Studies,Former Ambassador of Japan to Indonesia and to France
On February 7, 2025 (Japan time), the final act of a drama watched around the world came to a close at the U.S. District Court in Santa Ana, California. Judge John Holcomb sentenced Ippei Mizuhara (40), former interpreter for Los Angeles Dodgers star Shohei Ohtani, to 4 years and 9 months in prison, followed by 3 years of supervised release, for bank fraud and filing a false tax return.
On April 8, 2025, Japan’s regenerative medicine reached a historic turning point. Cuorips Inc., a biotech venture spun out of Osaka University, announced it had submitted a marketing authorization application to Japan’s Ministry of Health, Labour and Welfare (MHLW) for a “cardiomyocyte sheet” created from human induced pluripotent stem (iPS) cells. This is believed to be the world’s first marketing application aiming to commercialize a regenerative medicine product using iPS cells, and it has generated great anticipation across the scientific and medical communities.